Sofosbuvir/ledipasvir safety and efficacy for HCV patients with haemodialysis and liver cirrhosis: a small retrospective study

Sofosbuvir/ledipasvir safety and efficacy for HCV patients with haemodialysis and liver cirrhosis: a small retrospective study

Abstract Background Hepatitis C virus (HCV) infection is a high prevalent disease. Sofosbuvir/ledipasvir (SOF/LDV) can successfully treat HCV and it was until recently that SOF/LDV was approved by the FDA in haemodialysis patients, but not in patients with liver cirrhosis. This study reports patient...

Full description

Bibliographic Details
Main Authors: Ebtisam Boushi, Khaled Cheha, Noha Hedar, Rasha Almokdad, Mohammed Waleed Alassi, Ameer Kakaje
Format: Article
Language:English
Published: SpringerOpen 2021-10-01
Series:Egyptian Liver Journal
Subjects:
Cirrhosis
End-stage kidney disease
Haemodialysis
Sofosbuvir/ledipasvir
HCV
Online Access:https://doi.org/10.1186/s43066-021-00150-3

Internet

https://doi.org/10.1186/s43066-021-00150-3

Similar Items